Improving gout care after emergency department visits
Official title: Improving Gout Care After an Emergency Department Visit for Acute Gout
Run by University of Alabama at Birmingham · NCT06534554 · Data updated 2026-11-12
This study is testing a new way to help people with gout get better follow-up care after visiting the emergency room, especially for those in underserved communities in the Southeastern U.S.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Status | Recruiting |
| Started | June 18, 2024 |
| Main results expected | January 1, 2027 |
| Study ends | June 1, 2027 |
| Registry record updated | January 16, 2026 |
| Trial ID | NCT06534554 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who have experienced a confirmed acute gout flare and can communicate in English or Spanish.
✕Probably not a fit
Patients currently enrolled in another ongoing randomized controlled trial testing a different behavioral intervention may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to enhance the care provided to patients with gout who visit the emergency department (ED) by implementing a novel post-ED intervention. The focus is on improving outpatient follow-up care for acute gout flares, particularly among underserved populations in the Southeastern U.S., where gout prevalence is high. The intervention involves using patient navigators to reach out to patients within 36-72 hours after their ED visit to promote follow-up care and improve overall gout management. Additionally, the study seeks to increase participation of minority groups in biomedical research.
Why it matters
Potential benefit: If successful, this intervention could significantly improve the quality of gout care and health outcomes for patients following an ED visit.
How similar studies have gone: While this approach is innovative, similar studies focusing on improving follow-up care for chronic conditions have shown promise in enhancing patient outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years old * Able to communicate and understand English or Spanish * Confirmed acute gout flare by EMR review at ED visit Exclusion Criteria: * Enrollment in an ongoing RCT (NCT04075903) testing a behavioral intervention employing "storytelling".
Where it's running
-
University of Alabama at Birmingham
Birmingham, Alabama, United States Recruiting
Study contacts
- Study coordinator: Lesley E. Jackson, MD
- Email: lejackson@uabmc.edu
- Phone: (812) 322-0637
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Dotinurad in gout patients who can’t tolerate XOI or failed uricase treatment
This trial tests whether dotinurad can lower uric acid levels in adults with gout who can’t use certain standard medicines or have not benefited from uricase.
-
Orienting project on crystal deposits in gout, CPPD, and osteoarthritis
This project will follow adults with gout or CPPD and people with osteoarthritis to see if crystal deposits in joints and blood vessels change over time and relate to treatments or heart problems.
-
Remote monitoring for gout in primary care
This project will test a smartphone self-management app to help adults with gout and high urate levels manage their condition alongside GP follow-up.
-
Purified Cortrophin® Gel for treating acute gout flares at two dose levels
This study will try two single injections (40 U and 80 U) of Purified Cortrophin® Gel to see which dose better and more quickly reduces pain in adults having an acute gout flare.
-
IV PRX-115 at different dose schedules, with or without methotrexate, versus placebo for adults with gout
This trial will test whether IV PRX-115 given on different schedules, with or without low-dose methotrexate, can lower uric acid and be safe in adults whose gout is not controlled by standard urate-lowering drugs.
-
Dotinurad versus allopurinol for lowering uric acid in gout
This trial tests whether dotinurad lowers blood uric acid more than allopurinol in adults with gout.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.